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OBJECTIVES: Several large scale surveys conducted to measure time-preferences
of people in various fields, other than those in the health outcomes, have shown
that time-preferences follow non-constant exponential discounting. In pharmaco-
economic studies, however, all outcomesmeasures including quality-adjusted life-
years (QALYs) use discrete discounting. Disability-adjusted life-years (DALYs) is an
exception that is discounted using the non-constant exponential discounting ap-
proach. The objective of this study is to review the current literature on time-
preferences specific to health outcomes and compare the differences between
QALYs obtained through discrete discounting and non-constant exponential dis-
counting approaches. METHODS: We searched PubMed and EconLit for method-
ological studies examining time-preferences specific to health outcomes. We pro-
jected gains of 0.1 QALY/person/year over 1 to 75 years in a hypothetical dataset of
1000 persons. We calculated differences in present values of QALYs obtained
through discrete discounting and non-constant exponential discounting ap-
proaches, i.e. QALYs from discrete discounting subtracted by QALYs from non-
constant exponential discounting, at discount rates of 1.5%, 3%, 5%, and 7%, from 1
to 75 years. RESULTS:We found no studies that examined discounting approaches
specific to health outcomes. The differences in present values of QALYs, at 25, 50,
and 75 years, respectively, were: 1) 0.28%, 0.55%, and 0.83%, using a 1.5% discount
rate; 2) 1.1%, 2.2%, and 3.3%, using a 3% discount rate; 3) 3%, 5.9%, and 8.7%, using
a 5% discount rate; and 4) 5.7%, 11.1%, and 16.1%, using a 7% discount rate.
CONCLUSIONS: We found no published research comparing discrete discounting
to non-constant exponential discounting approaches for QALYs. Over long time
horizons, we found small but conceptually important differences between QALYs
estimated by these approaches. Therefore, we recommend future studies to ad-
dress time-preferences specific to determine if non-constant exponential dis-
counting is relevant to health outcomes such as QALYs.
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OBJECTIVES: The Center for Medicaid and Medicare Services (CMS) has created
plan Star ratings that indicate the quality of Medicare plans. In 2012, CMS added
three pharmacy measures that focus on member medication adherence, i.e. oral
diabetes medications, hypertension medication (ACEI or ARB), and cholesterol
medication (statins). To proactively identify patients at risk for non-adherence, a
multi-variate regression prediction model was developed to create individual per-
sistency risk scores.METHODS: The predictive model is created using prescription
drug and medical claims from a large managed care database. Medicare and com-
mercially insured patients over age 55 from 2008-2010 who are new to the Star
rating medication categories are included. Patients included in the model have a
full 18 months of continuous enrollment in the health plan (6 month drug naïve
period, 12 months of follow up). The predictors are created from the 6 month pre
period and include: a) socio-economic factors; b) medical characteristics (e.g.
Charlson Comorbidity Index); and c) drug characteristics (i.e. drug cost and past
chronic drug adherence). RESULTS: Multivariable analysis of study outcomes will
be conducted using appropriate regressionmodels based on the distribution of the
measure. A logistic regressionmodel will be estimated (1 for at least 80% PDC,0
for non-compliance). Results of a logistic regressionwill be presented as odds ratios
associated with each independent variable. The parameter estimates from the
above econometric model will be retained and used to estimate the probability of
non-compliance on a new set of patients. To test the accuracy of the predictive
model, we will choose a random sample of patients new to these medications in
2011, as exhibited by the average PDC in each risk group (high, medium, low).
CONCLUSIONS: An adherence predictive model can be useful to identify patients
who may benefit from a drug adherence intervention program.
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EVALUATION OF DECISION ANALYTIC MODELS IN COST-EFFECTIVENESS
ANALYSIS IN KOREA: FROM GUIDELINE TO PRACTICE
Bae S, Lee S, Lim SH
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OBJECTIVES: Korea’s Health Insurance Review and Assessment Service (HIRA) has
been in charge of formulating economic evaluation guideline and evaluating sub-
missions for reimbursement decision. The purpose of this study is to observe cur-
rent practice patterns of using decision analyticmodels in submissions considered
by HIRA.METHODS: Thirty-four dossiers were submitted by industry from January
2007 until December 2009, and they were evaluated by two independent research-
ers at HIRA. The adherence to current HIRA’s recommendation was assessed.
RESULTS: Out of 34 submissions, 23 applied model-based evaluations, and more
than half (14) submissionswere based onmarkovmodeling. Dynamicmodels were
not applied any of the submissions. Submissions frequently omitted the justifica-
tion of the assumptions, definition of markov states or cycle length. Parameter
search /selection criteria were rarely provided, and usually extrapolated in favor of
the applicants. Transparencywas lacking especiallymodelswith long timehorizon
and multiple assumptions, and submitted models were rarely validated.
CONCLUSIONS:Decision analytic models are frequently applied in economic eval-
uation dossiers, yet the quality of provided models varied greatly. Revised HIRA’s
guideline could specify the minimum standard of modeling to increase the com-
parability of submitted dossiers.
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OBJECTIVES: To define an operational modelling framework intended to help the
design of Performance-Based Risk-Sharing (PBRS) schemes. A time-to-event end-
point is used as a performance criterion. Such survival endpoints are commonly
used in clinical studies, notably in oncology where PBRS schemes are gaining
momentum. METHODS: The framework is based on an open population model
with a monthly cycle and 3-year time horizon from launch (i.e. when enrolment
into the PBRS scheme starts). Entry into the model (i.e. the progressive arrival of
new patients into the PBRS scheme) is determined by market diffusion assump-
tions and is modelled using a Logistic function. Exit from the model (i.e. patients
experiencing the event or dying from any cause) is determined by survival curves
from clinical/epidemiological studies and is modelled using a Weibull function.
The model accommodates different treatment dosing schedules and performance
levels (i.e. minimum survival times guaranteed). Multiple PBRS scenarios can be
run and compared in terms of their operational and financial implications. Addi-
tionally, the effect of potential revisions of a PBRS scheme terms and conditions
can also be examined as real-life information becomes available following scheme
implementation (i.e. Bayesian updating). RESULTS: For example, assuming 1,000
patients enrolled in a PBRS scheme, with a monthly dosing schedule and given
diffusion (Logistic 5.0; 0.4) and survival (Weibull 0.7; k27.0) assumptions,
the model predicts that 1937 (6970), 4050 (7861) and 9282 (4420) doses will be given
to non-responding (responding) patients with 12, 18 and 24 months minimum
survival time guaranteed scenarios, respectively. CONCLUSIONS: This framework
provides both payer and manufacturer with valuable insight into the operational
and financial dimensions of the potential PBRS schemes they may contemplate as
they negotiate patient access conditions. Both parties can better anticipate the
implications of the schemes and better plan resources, logistics and financial ar-
rangements accordingly.
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OBJECTIVES: To evaluate a web-based software program which incorporates
Markov Chain Monte Carlo (MCMC) analysis to compare the cost-effectiveness of
any two treatments, allowing modifiable inputs of key variables. METHODS: A
web-based software program was developed, which incorporates Markov Chain
Monte Carlo (MCMC) analysis to compare the cost-effectiveness of any two treat-
ments. The online software program was based on calculation methods described
in “Decision Making in Health and Medicine” textbook from Hunink et al. The
MCMC web-based program computes and graphically displays the results, using
JavaScript algorithms and is available as freeware at www.healthstrategy.com.We
compared the online resultswith analyses usingDecisionMaker software available
from UMDNJ.edu. The variable inputs that can be modified in the web-based ap-
plication include: state transition probabilities, number of patients, number of
cycles, cost per state, and utility per state. RESULTS: The web-based tool creates
plots of incremental costs versus incremental utilities, in cost-effectiveness quad-
rants; and if death is the absorbing state, also graphs life expectancy curves for two
treatment comparisons. As an example of the similarity of findings, when consid-
ering three transition states per treatment, the online software versus the Decision
Maker model results were as follows: treatment cost (means: $1417 vs. $1300 and
standard deviations: 1706 vs. 1604); treatment effectiveness (means: 7.6 vs. 7.8 and
standard deviations: 7.2 vs. 7.0). CONCLUSIONS:With this online MCMC program,
the user can input their own therapy parameters, and then generate key means
and standard deviations, incremental costs, incremental utilities, life expectancy
curves, and incremental cost effectiveness ratios. MCMC has advantages over
Markov cohort analyses because means and standard deviations can be generated
from theMCMC calculations. This web-based application has potential benefit as a
basic educational tool for students and health professionals interested in exploring
these analytical approaches.
PRM34
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OBJECTIVES:Markov models are often used in Health Economics to represent dis-
ease progression in Cost-Utilitymodels. The transition probabilities, however,may
be difficult to populate when the data are limited. This note applies the Markov
matrix approximation method using vector autoregression (VAR) to estimate the
transition matrix when the sample size is small.METHODS:We compare the per-
formance of the standard (count) method versus the VAR method to estimate
transition probabilities in small samples. For the count method, one counts the
A164 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
transitions from state to any other state in the data and then divides the counts by
the number of occurrences for each . The VARmethod follows Tauchen (1986) and
Terry and Knotek (2011). We compare the two methods using Monte Carlo simula-
tions by generating small samples from different data generating processes (DGPs)
and comparing the mean squared errors made by each method versus the true
transition matrix. We employ two DGPs to populate the entries of our underlying
transition probability matrices in our study: 1) A normal distribution with large
variance (DPG1), and 2) a uniform distributionwith small variance (DGP2). We then
normalize each row so they sum to 1. RESULTS: In DGP1, the VAR outperforms the
count method in small samples (N  10 or 30) and the count method marginally
outperforms the VAR method in the large sample (N  50). For DGP2, VAR outper-
forms in small samples and both methods perform similarly in the large sample.
We propose a combination of the two methods by increasing the weight on the
count method when the sample size increases relative to the size of the matrix.
CONCLUSIONS: By applying this methodology in Health Economics modeling, it
allows the researcher to utilize Markov models in situations previously infeasible
due to a paucity of data.
RESEARCH ON METHODS – Patient-Reported Outcomes Studies
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OBJECTIVES:Willingness-to-pay (WTP) analysis is a method for the monetization
of a population’s preference for a particular medication and may be determined
using a bidding game where participants are asked if they would be willing to pay
a particular amount, starting with a pre-determined value and oscillating between
a series of new WTP amounts based on their previous answer. Starting point bias
has been previously reported in the literature. The objective of the present study
was to ascertain if any bias was introduced by applying higher or lower starting
values to a bidding game. METHODS: An online survey was presented to mem-
bers of the general public in Ontario, Canada, who were presented with two
treatment delivery options (inhaler vs. injection) for a treatment of pulmonary
arterial hypertension. Participants who selected the inhaler were randomly as-
signed a starting value (CAD$1, $2 or $5) and were asked to identify their WTP in
terms of additional monthly insurance premiums. The minimum and maxi-
mum bidding game values were set at CAD$0.01 and CAD$50.00; participants
who agreed to pay CAD$50.00 were allowed to input a higher WTP explicitly, as
desired. The Kruskall-Wallis non-parametric test was applied to explore the
differences in mean WTP associated with each starting value. RESULTS: Eighty-
six participants reported a meanWTP of CAD$43.15 for the inhaler in additional
monthly insurance premium. The mean WTP were CAD$37.55, CAD$49.36 and
CAD$40.31 for participants whowere assigned to a starting point of CAD$1, $2 or
$5, respectively. No significant difference in WTP values was observed between
the groups. CONCLUSIONS:The starting value did not appear to introduce a bias in
the bidding game.
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OBJECTIVES: Different countries might have similar health preferences due to
cultural or economic factors. The aim of this study is to identify whether there are
groups of countrieswith similar health-state valuations.METHODS:A cluster anal-
ysis was performed for the 242 states of the EQ-5D valuations for 23 published
studies in 18 countries. The perfect health state was not included. The Ward algo-
rithm with the Euclidean measure and the hierarchical clustering technique were
used in order to identify the optimal number of clusters and the clusters them-
selves. The features of the resulting clusters were studied and whether there were
similarities in the countries belonging to the same cluster. The effect of the valu-
ation methodology, Visual Analogue Scale (VAS) or Time Trade Off (TTO), was also
taken into account. RESULTS: Five clusters were identified: 1) Germany-TTO, Neth-
erlands-TTO, Denmark-TTO, Argentina-TTO, Poland-TTO; 2) Belgium-VAS, Eu-
rope-VAS, New Zealand-VAS, Spain-VAS, UK-VAS, Denmark-VAS, Germany-VAS,
Slovenia-VAS; 3) Spain-TTO, UK-TTO; 4) Japan-TTO, USA-TTO, Zimbabwe-TTO,
Hispanic USA-TTO, South Korea 2009-TTO, Finland-VAS, Argentina, VAS; and 5)
South Korea 2008-TTO. Valuations are very sensitive to the preference elicitation
methodology. Hence, valuations for a country may be more similar to the valua-
tions of another country with the same methodology than to the same country
with a different methodology. Countries in the same cluster tend to have cultural
similarities (e.g. European countries with the same methodology tend to belong in
the same cluster) but a particular cluster grouped otherwise dissimilar countries
and methodologies: Japan-TTO, USA-TTO, Zimbabwe-TTO, and Argentina-VAS.
CONCLUSIONS: Health-state valuations tend to be clustered in a few groups of
countries that share cultural or economic features. These results can be used in
sensitivity analyses when performing cost-utility analysis.
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OBJECTIVES: Health economics research aims to maximise health gain within a
given budget constraint, and is predominantly achieved through themaximisation
of the quality-adjusted-life-year (QALY). Historically, the QALY assumes that indi-
viduals derive utility only from the consequences of processes and not from the
processes themselves. This assumption of narrow consequentialism suggests
health care consumers gain no benefit from the consumption of health, but that its
value is determined exclusively through health outcomes. There is growing inter-
est, however, in being able to differentiate between treatments with different pro-
cesses, such as delivery methods, in quantitative terms. This study aimed to iden-
tify and review published empirical studies which include a measure of process
utility (PU) which could be incorporated into the QALY calculation. METHODS: A
literature reviewwas performed inMedline using the search term “process utility”.
Additional searcheswere performed to identify studies not using this specific term,
for example: treatment-related attributes AND (utilities OR utility
measurement). RESULTS: Fifteen studies were identified. A variety of approaches
were used to detect and measure PU: 4 studies used standard-gamble techniques;
5 studies used time-trade-off techniques; 2 studies used conjoint analysis; 1 study
used SF-36 data; 3 studies used waiting-trade-off techniques. Eight studies evalu-
ated treatments: 5 in diabetes and the remainder in gallstone disease, HIV and pain
treatments; 6 studies evaluated testing/screening procedures and 1 study evalu-
ated preventative care. All studies identified the presence of PU. Utility decrements
ranged from 0.03-0.14 for different drug delivery methods, and 0.0005-0.12 for dif-
ferent dosing strategies. CONCLUSIONS:Although there is no universally accepted
methodology for the detection and measurement of PU, evidence to date does
support its existence. Thewide range in values and approaches suggests that stan-
dardisation of methods around the most valid approach is highly desirable. With-
out this type of consensus, comparability and validity of results will be limited.
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OBJECTIVES: To study post-transplant experience of disease and treatment among
members of the free online PatientsLikeMe® Organ Transplant Community.
METHODS: A review of the literature, existing questionnaires, and analysis of dis-
cussions between transplant recipients on the website PatientsLikeMe.com was
used to generate items for a survey in patients’ own voice. Cognitive debriefing
(n7) was used to refine the items. Including patient and treatment characteristics
the resulting online questionnaire contained 170 items informing 17 dimensions of
patient experience. We surveyed patients in the US who had received a single
organ. RESULTS: Twenty-eight percent of current, sampledmembers responded (n
 116, median completion time  22 minutes). The sample was 63% female, 72%
aged 45 or older, 77% non-Hispanic white, 41% college graduate, 62% kidney recip-
ients, 70% transplanted 2 or more years ago. There were no significant differences
between respondents and non-respondents. Over 40% of respondents rated their
health as very good or excellent; over 60% rated their life since transplant as
better than expected. On average, 7 symptoms (of 41) were reported as at least
moderately bothersome in the past 4 weeks. More symptoms correlated with
worse experience of physical, mental, emotional, and social functions and rela-
tionswith the health care team. Patientswithmore symptoms also reported poorer
immunosuppressant adherence (F4,1252.66, p  0.036). Regression analysis
showed that disease-specific impact and physical limitation were most important
to overall status. Analysis of variance showed the scales varied in sensitivity to
reported group differences in overall health, perceived adherence, and comparison
of current situationwith what the patient expected. Reliability was above .79 for 15
of 18 scales. Scale correlations were moderate. CONCLUSIONS: Using the Patient-
sLikeMe online Organ Transplantation community questions were adapted from
existing PROmeasures andnewquestionswere developed tomeasure both generic
and condition-specific experiences important to post-transplant patients.
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OBJECTIVES: Starting point (SP) bias has been reported in somewillingness-to-pay
(WTP) analyses using a bidding game (BG) approach. The objective of the present
study was to systematically reviewWTP analyses which used more than one SP to
ascertain if any bias was observed. METHODS: Using OVID MEDLINE® for 1996-
2011 and the keywords [Bidding AND (Willingness to payORWillingness-to-pay OR
WTP)], two reviewers independently identified and examinedWTP analyses which
applied more than one SP to a BG approach and which discussed any associated
bias. Additional publications were also extracted from the references of relevant
articles. Any discrepancy between the two reviewers was resolved through
consensus. RESULTS: From 51 articles yielded by the literature search, 12 met the
inclusion criteria and a further 5 were classified as secondary evidence (publica-
tions reporting on SP bias without presenting numerical data). Relevant publica-
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